Secondary analysis of 73 MSA patients with neurogenic orthostatic hypotension: of 40 randomised to continue ampreloxetine or switch to placebo, 6-week treatment failure was 15% vs 40% (p=0.11, not significant); symptoms (secondary) worsened on placebo.
Secondary analysisn = 73
Freeman et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial